TY - JOUR
T1 - Monoclonal antibodies in chronic lymphocytic leukemia
AU - Ferrajoli, Alessandra
AU - Faderl, Stefan
AU - Keating, Michael J.
PY - 2006/9
Y1 - 2006/9
N2 - Multiple options are now available for the treatment of chronic lymphocytic leukemia. Over the last 10 years, monoclonal antibodies have become an integral part of the management of this disease. Alemtuzumab has received approval for use in patients with fludarabine-refractory chronic lymphocytic leukemia. Rituximab has been investigated extensively in chronic lymphocytic leukemia both as a single agent and in combination with chemotherapy and other monoclonal antibodies. Epratuzumab and lumiliximab are newer monoclonal antibodies in the early phase of clinical development. This article will review the monoclonal antibodies more commonly used to treat chronic lymphocytic leukemia, the results obtained with monoclonal antibodies as single agents and in combination with chemotherapy, and other biological agents and newer compounds undergoing clinical trials.
AB - Multiple options are now available for the treatment of chronic lymphocytic leukemia. Over the last 10 years, monoclonal antibodies have become an integral part of the management of this disease. Alemtuzumab has received approval for use in patients with fludarabine-refractory chronic lymphocytic leukemia. Rituximab has been investigated extensively in chronic lymphocytic leukemia both as a single agent and in combination with chemotherapy and other monoclonal antibodies. Epratuzumab and lumiliximab are newer monoclonal antibodies in the early phase of clinical development. This article will review the monoclonal antibodies more commonly used to treat chronic lymphocytic leukemia, the results obtained with monoclonal antibodies as single agents and in combination with chemotherapy, and other biological agents and newer compounds undergoing clinical trials.
KW - Chemoimmunotherapy
KW - Chronic lymphocytic leukemia
KW - Monoclonal antibodies
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=33750056973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750056973&partnerID=8YFLogxK
U2 - 10.1586/14737140.6.9.1231
DO - 10.1586/14737140.6.9.1231
M3 - Review article
C2 - 17020457
AN - SCOPUS:33750056973
SN - 1473-7140
VL - 6
SP - 1231
EP - 1238
JO - Expert review of anticancer therapy
JF - Expert review of anticancer therapy
IS - 9
ER -